Live Breaking News & Updates on Endocrinology Michael

May 19, 2021
Current guidelines strongly recommend use of the therapy for cardiology, diabetes patients
In a series of presentations at ACC.21, the virtual meeting of the American College of Cardiology, researchers delivered data to confirm two observations about cardiovascular outcomes in heart failure patients with or without type 2 diabetes (T2D) and/or chronic kidney disease (CDK). First, the use of SGLT2 inhibitors is associated with reduced risk of cardiovascular death, worsening heart failure, and/or hospitalization for heart failure, and second, SGLT2i agents are woefully underused.
In a presentation titled, “Just Go With the Flo(zin): SGLT2i Should Be Added to A Few, Some, Most, All HFrEF Patients?”, Glenn Herrington, PharmD, Ambulatory Care Cardiology Pharmacist at New Hanover Regional Medical Center in Wilmington, North Carolina, reviewed findings from EMPA-REG OUTCOME, CANVAS PROGRAM,DECLARE-TIMI 58, VERTIS CV, DAPA-HF, and EMPEROR-REDUCED to assess b ....

United States , North Carolina , South Korea , Michaelj Blaha , Glenn Herrington , Rishav Adhikai , Peggy Peck , Boehringer Ingelheim Eli Lilly , Wayne Huey Herng Sheu , American Heart Association , American College Of Cardiology , American Diabetes Association , Johns Hopkins University School Of Medicine , National Prescription Audit , Aetna Foundation , Company Diabetes Alliance , Amgen Foundation , Novo Nordisk , American College , Should Be Added , Ambulatory Care Cardiology Pharmacist , New Hanover Regional Medical Center , Hopkins University School , Hopkins Associate Professor , Endocrinology Michael , Prescription Audit ,